Cytokine inhibitors in the treatment of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 2, Issue 2, 2002, Pages 135-149

  Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cytokines; IL 1; IL 1Ra; Rheumatoid arthritis; Soluble receptors; TNF

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CERTOLIZUMAB PEGOL; CYTOKINE INHIBITOR; ENZYME INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 6; LENERCEPT; METHOTREXATE; OLIGONUCLEOTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PEGYLATED TUMOR NECROSIS FACTOR RECEPTOR; PROTEINASE INHIBITOR; RECEPTOR SUBTYPE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SOLUBLE INTERLEUKIN 1 RECEPTOR TYPE 2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; IMMUNOPATHOLOGY; INFECTIOUS COMPLICATION; LUPUS ERYTHEMATOSUS; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INTERLEUKIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035989752     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.2.135     Document Type: Review

References (126)

1. Rheumatoid arthritis. Pathophysiology and implications for therapy
2. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
3. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint
4. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
5. Macrophage- and neutrophil-dominant arthritis in transgenic mice
6. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
7. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
8. Anti-rumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
9. Synovium as a source of interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis
10. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α
11. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-I production in rheumatoid arthritis
12. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
13. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
14. Therapeutic efficacy of multiple intravenous infusions of tumor necrosis α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
15. Infliximab and methotrexate in the treatment of rheumatoid arthritis
16. 102-Wk clinical & radiologic results from the ATTRACT trial: A 2 year, randomized, controlled, Phase 3 trial of infliximab (Remicade®) in patients with active RA despite MTX
17. Efficacy and safety of Remicade (infliximab) plus arava (leflunomide) in rheumatoid arthritis (RA)
18. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
19. 2E7: A fully human anti-tumour necrosis factor α monoclonal antibody
20. The fully human anti-TNF antibody adalimumab (D2E7) in combination with methotrexate (MTX) in the treatment of active rheumatoid arthritis. Results of a two-year study
21. Efficacy of a novel pegylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis
22. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: Implications for local actions of tumor necrosis factor alpha
23. A novel domain within the 55 kd TNF receptor signals cell death
24. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
25. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis-dermatomyositis: A biological marker of disease activity with a possible role in the lack of acute-phase protein response
26. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity
27. Soluble tumor necrosis factor (TNF) receptor are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
28. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion
29. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
30. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
31. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial
32. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
33. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
34. Updates consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
35. Long-term safety and efficacy of eranercept in patients with rheumatoid arthritis
36. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a European Phase II trial
37. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality
38. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor Type I: A clinical update
39. Antiarthritic activity of soluble tumor necrosis factor receptor Type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
40. The efficacy and safety of pegylated recombinant methionyl human soluble tumor necrosis factor receptor Type I (PEG sTNF-RI; p55) in a randomized placebo-controlled, clinical study of patients with rheumatoid arthritis (RA)
41. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
42. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
43. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells
44. Cloning of disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α
45. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis
46. Biology of TACE inhibition
47. Imbalance between interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-I) in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
48. The transmembrane form of tumour necrosis factor is the prime activating ligand for the 80 kDa TNF receptor
49. An essential role for ectodomain shedding in mammalian development
50. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell culture
51. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
52. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. By what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis
53. Infliximab-induced aseptic meningitis
54. Joint inflammation and cartilage destruction may occur uncoupled
55. IL-1 inhibitors: Novel agents in the treatment of rheumatoid arthritis
56. Characterization of a low molecular weight isoform of interleukin-1 receptor antagonist
57. Extracellular release of the Type I intracellular IL-1 receptor antagonist from human airway epithelial cells. Differential effects of IL-4, IL-13, IFNγ, and corticosteroids
58. Mechanical deformation promotes secretion of IL-1α and IL-1 receptor antagonist
59. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: A potential mechanism of symptom resolution
60. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1β
61. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice
62. Altered susceptibility to collagen induced arthritis in transgenic mice with aberrant expression of IL-1 receptor antagonist
63. Development of chronic inflammatory polyarthropathy ressembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice
64. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats
65. Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits
66. The effect of an interleukin-1 receptor antagonist protein on Type II collagen-induced arthritis and antigen-induced arthritis in mice
67. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant interleukin-1 receptor antagonist
68. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
69. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
70. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis
71. A slow release formulation of interleukin-1 receptor antagonist (IL-1Ra) exhibits improved in vivo activity
72. Effects of interleukin-1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats
73. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients
74. Binding of II-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids
75. Recombinant human interleukin-1 receptor Type I in the treatment of patients with active rheumatoid arthritis
76. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by Type II interleukin-1 soluble receptor and hindered by Type I interleukin-1 soluble receptor
77. Effects of soluble interleukin-1 Type II receptor on rabbit antigen-induced arthritis: Clinical, biochemical and histological assessment
78. The Type II receptor of interleukin-1 inhibits murine collagen-induced arthritis
79. Functional genomic analysis of Type II IL-1β decoy receptor: Potential for gene therapy in human arthritis and inflammation
80. Biologic basis for interleukin-1 in disease
81. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis
82. Identification of a nuclear localization sequence within the structure of the human interleukin-1α precursor
83. The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein
84. Interleukin-1β converting enzyme inhibition blocks progression of Type II collagen-induced arthritis in mice
85. Response to local inflammation of IL-1β-converting enzyme-deficient mice
86. Generation of biologically active IL-1β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1β processing
87. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects
88. Different roles of turnout necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis
89. Combination benefit of treatment with recombinant humen interleukin-1 receptor antagonist (IL-1Ra) and pegylated recombinant human soluble tumor necrosis factor receptor Type I (PEG sTNF-RI) in animal models of rheumatoid arthritis
90. Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone
91. Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators
92. Selective proteasome inhibition artenuates experimental polyarthrids via inhibition of nuclear transcription factor κB (NFκB) activation
93. Essential role of T cell NF-κB activation in collagen-induced arthritis
94. The role of Jun, Fos and AP-1 complex in cell-proliferation and transformation
95. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice
96. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction
97. Etanercept in children with polyarticular juvenile rheumatoid arthritis
98. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
99. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study
100. Effect of infliximab on sight-threatening panuveitis in Behçet's disease
101. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
102. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis, a randomized trial
103. Infliximab for the treatment of fistulas in patients with Crohn's disease
104. Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial
105. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
106. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in the development of antigen-induced immunopathology
107. IL-1 independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis
108. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
109. IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis
110. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells
111. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
112. The acute-phase proteins and other systemic responses to inflammation
113. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
114. Interleukin 6 is required for the development of collagen-induced arthritis
115. Interleukin 6 plays a key role in the development of antigen-induced arthritis
116. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses
117. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
118. A double-blind, randomized, placebo-controlled trial of anti-interleukin-6 (IL-6) receptor monoclonal antibody in rheumatoid arthritis (RA)
119. IL-1β and IL-6 selectively induce transforming growth factor-β isoforms in human articular chondrocytes
120. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA)
121. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity
122. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice
123. Osteoprotegerin ligand is a cytokine that regulates osteoclast differenciation and activation
124. The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis
125. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
126. Direct gene delivery strategies for the treatment of rheumatoid arthritis